Recent years, HDAC inhibitors have been developed to antagonize the reduced global histone acetylation observed in many tumor types, including NSCLC.69 The combination of HDAC3 inhibitor and trametinib has shown therapeutic benefits in genetically engineered mouse models of NSCLC. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.